Abbvie Plc was Ironwood Pharmaceuticals’s largest revenue line in fiscal 2025, bringing in $295.99M of $298.00M (99%).
| Counterparty Name | FY 2013 | FY 2014 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Abbvie Plc | $403.94M | $436.02M | $346.39M | $295.99M | |||
| Allergan | — | — | — | — | |||
| Allergan (North America) | — | — | — | — | |||
| Almirall | — | — | — | — | |||
| Almirall (Europe) | — | — | — | — | |||
| Astellas Pharma Inc | $2.00M | $1.80M | $1.67M | $1.69M | |||
| Astellas | — | — | — | — | |||
| Astellas (Japan) | — | — | — | — | |||
| Astrazeneca | $635.00K | $430.00K | $364.00K | $321.00K | |||
| Astrazeneca (China, Hong Kong & Macau) | — | — | — | — | |||
| Total | $406.58M | $438.25M | $348.43M | $298.00M |
Ironwood Pharmaceuticals brought in $298.00M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 14.5% from $348.43M in fiscal 2024. Abbvie Plc was the largest at $295.99M (99.3%), ahead of Astellas Pharma Inc at $1.69M (0.6%) and Astrazeneca at $321.00K (0.1%).
From fiscal 2022 to 2025, combined revenue from these revenue lines fell from $406.58M to $298.00M, a compound annual decline of 9.8%. Abbvie Plc's share held steady at about 99.3%.
Collaborative Arrangements Revenue was Ironwood Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $296.15M of $300.24M (99%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative Arrangements Revenue | $410.60M | $442.74M | $351.41M | $296.15M | ||||||
| Sale Of Active Pharmaceutical Ingredient | — | — | — | — | ||||||
| Collaborative Arrangement, Promotion Agreements | — | — | — | — | ||||||
| Collaborative Arrangement, Co-Promotion Agreements | — | — | — | — | ||||||
| Product Revenue, Net | — | — | — | — | ||||||
| Collaborative Arrangement, Collaboration & License Agreements | — | — | — | $2.01M | ||||||
| Royalty | — | — | — | $2.00M | ||||||
| Collaborative Arrangement, Other Agreements | — | — | — | $87.00K | ||||||
| Total | $410.60M | $442.74M | $351.41M | $300.24M |
Ironwood Pharmaceuticals brought in $300.24M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Ironwood Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $351.41M. Collaborative Arrangements Revenue was the largest at $296.15M (98.6%), ahead of Collaborative Arrangement, Collaboration & License Agreements at $2.01M (0.7%) and Royalty at $2.00M (0.7%). The remaining line, Collaborative Arrangement, Other Agreements, brought in $87.00K.
Ironwood Pharmaceuticals began breaking out Collaborative Arrangement, Collaboration & License Agreements in fiscal 2025 and Royalty in fiscal 2025.
North America was Ironwood Pharmaceuticals’s largest region in fiscal 2025, bringing in $292.36M of $295.99M (99%).
| Geography | FY 2014 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| North America | $401.50M | $433.24M | $343.15M | $292.36M | ||
| Japan | — | — | — | — | ||
| Europe | — | — | — | — | ||
| China, Hong Kong, & Macau | — | — | — | — | ||
| Europe & Other | $2.44M | $2.78M | $3.24M | $3.63M | ||
| Total | $403.94M | $436.02M | $346.39M | $295.99M |
Ironwood Pharmaceuticals brought in $295.99M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 14.6% from $346.39M in fiscal 2024. North America was the largest at $292.36M (98.8%), ahead of Europe & Other at $3.63M (1.2%).
From fiscal 2022 to 2025, combined revenue from these regions fell from $403.94M to $295.99M, a compound annual decline of 9.8%. North America's share of the total fell from 99.4% to 98.8%.
Ironwood Pharmaceuticals (IRWD) reports its revenue by counterparty name, by product and service and by geography. In fiscal 2025, Abbvie Plc was its largest revenue line, bringing in $295.99M (99.3% of the total), followed by Astellas Pharma Inc at $1.69M (0.6%).
Abbvie Plc was Ironwood Pharmaceuticals' largest revenue line in fiscal 2025, bringing in $295.99M, or 99.3% of the $298.00M total across its three revenue lines.
Collaborative Arrangements Revenue was Ironwood Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $296.15M, or 98.6% of the $300.24M total across its four product and service lines.
North America was Ironwood Pharmaceuticals' largest region in fiscal 2025, bringing in $292.36M, or 98.8% of the $295.99M total across its two regions.
Every figure comes from Ironwood Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Ironwood Pharmaceuticals gives it, and years follow its fiscal calendar.
Ironwood Pharmaceuticals' revenue by counterparty name goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.